You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MK-3475

Showing 1 - 25 of 1,213
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, Renal Cell Carcinoma, Melanoma Trial (Pembrolizumab co-formulated with hyaluronidase, Pembrolizumab)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • +2 more
  • Pembrolizumab co-formulated with hyaluronidase
  • Pembrolizumab
  • (no location specified)
Oct 19, 2023

Squamous Cell Carcinoma Trial (MK-3475A)

Not yet recruiting
  • Squamous Cell Carcinoma
  • MK-3475A
  • (no location specified)
Sep 11, 2023

Hepatocellular Carcinoma Trial (Pembrolizumab)

Active, not recruiting
Has Results
  • Hepatocellular Carcinoma
  • Pembrolizumab
  • (no location specified)
Dec 15, 2022

Urothelial Cancer Trial (pembrolizumab)

Completed
Has Results
  • Urothelial Cancer
  • pembrolizumab
  • (no location specified)
Aug 18, 2022

Metastatic NSCLC Trial (Pembrolizumab coformulated with hyaluronidase, Pemetrexed, Cisplatin)

Not yet recruiting
  • Metastatic Non-small Cell Lung Cancer
  • Pembrolizumab coformulated with hyaluronidase
  • +6 more
  • (no location specified)
Jan 27, 2023

Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer Trial (favezelimab/pembrolizumab, pembrolizumab, lenvatinib)

Not yet recruiting
  • Solid Tumor
  • +2 more
  • favezelimab/pembrolizumab
  • +2 more
  • (no location specified)
Sep 7, 2023

Non-small Cell Lung Carcinoma Trial (Pembrolizumab, Paclitaxel, Carboplatin)

Completed
Has Results
  • Non-small Cell Lung Carcinoma
  • Pembrolizumab
  • +7 more
  • (no location specified)
Oct 13, 2022

Metastatic Castration-resistant Prostate Cancer Trial (Pembrolizumab, Enzalutamide)

Completed
  • Metastatic Castration-resistant Prostate Cancer
  • (no location specified)
Aug 16, 2022

Hepatocellular Carcinoma Trial (biological, drug, other)

Completed
Has Results
  • Hepatocellular Carcinoma
  • Pembrolizumab
  • +2 more
  • (no location specified)
Aug 30, 2022

Renal Cell Carcinoma Trial (Pembrolizumab)

Completed
Has Results
  • Renal Cell Carcinoma
  • Pembrolizumab
  • (no location specified)
Aug 17, 2022

Bladder Cancer Trial in Japan (drug, procedure, radiation)

Not yet recruiting
  • Bladder Cancer
  • MK-3475
  • +3 more
  • Kobe, Hyogo, Japan
  • +3 more
May 26, 2023

Head and Neck Squamous Cell Cancer Trial (pembrolizumab, methotrexate, docetaxel)

Completed
Has Results
  • Head and Neck Squamous Cell Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 24, 2022

NSCLC Trial in Marietta, Taichung City, Tainan (Sacituzumab Govitecan, Pembrolizumab)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Sacituzumab Govitecan
  • Pembrolizumab
  • Marietta, Georgia
  • +2 more
Jan 27, 2023

Bladder Cancer Trial (pembrolizumab)

Active, not recruiting
  • Bladder Cancer
  • Pembrolizumab
  • +2 more
  • (no location specified)
Oct 11, 2022

Melanoma Trial in Worldwide (Pembrolizumab Dose C, Pembrolizumab Dose A, Pembrolizumab Dose B)

Active, not recruiting
  • Melanoma
  • Pembrolizumab Dose C
  • +3 more
  • Orange, New South Wales, Australia
  • +14 more
Jan 19, 2023

Melanoma Trial (pembrolizumab, )

Active, not recruiting
Has Results
  • Melanoma
  • pembrolizumab
  • placebo
  • (no location specified)
Aug 18, 2022

Recurrent Head Neck Cancer, Metastatic Head Neck Cancer Trial (Pembrolizumab, Cisplatin, Carboplatin)

Active, not recruiting
Has Results
  • Recurrent Head and Neck Cancer
  • Metastatic Head and Neck Cancer
  • Pembrolizumab
  • +4 more
  • (no location specified)
Aug 18, 2022

Hodgkin Lymphoma Trial (pembrolizumab)

Active, not recruiting
  • Hodgkin Lymphoma
  • pembrolizumab
  • (no location specified)
May 30, 2022

Triple Negative Breast Cancer Trial in New York (Merck 3475 Pembrolizumab, Intraoperative radiation therapy (IORT))

Recruiting
  • Triple Negative Breast Cancer
  • Merck 3475 Pembrolizumab
  • Intraoperative radiation therapy (IORT)
  • New York, New York
    Columbia University Irving Medical Center
Oct 10, 2022

Advanced or Metastatic Solid Tumors Trial in Toronto, Genève, Bellinzona (MK-6598, Pembrolizumab)

Recruiting
  • Advanced or Metastatic Solid Tumors
  • Toronto, Ontario, Canada
  • +2 more
Jan 19, 2023

Renal Cell Carcinoma Trial (Pembrolizumab, Axitinib, Sunitinib)

Active, not recruiting
Has Results
  • Renal Cell Carcinoma
  • Pembrolizumab
  • +2 more
  • (no location specified)
Aug 17, 2022

Hodgkin Lymphoma Trial (pembrolizumab, brentuximab vedotin)

Active, not recruiting
  • Hodgkin Lymphoma
  • pembrolizumab
  • brentuximab vedotin
  • (no location specified)
Aug 18, 2022

Cancer of Head and Neck, Head Neck Cancer, Tumors, Head and Neck Trial in Boston, Saint Louis, New York (biological, procedure,

Active, not recruiting
  • Cancer of Head and Neck
  • +5 more
  • MK-3475 (neoadjuvant)
  • +6 more
  • Boston, Massachusetts
  • +2 more
Dec 9, 2022

Metastatic Solid Tumors, Advanced Solid Tumors Trial (MK-0472, Pembrolizumab)

Not yet recruiting
  • Metastatic Solid Tumors
  • Advanced Solid Tumors
  • (no location specified)
May 2, 2023

Tumors, Colorectal Cancer Trial in Grand Rapids, Nashville, Kirkland (MK-8353, Pembrolizumab)

Completed
  • Neoplasms
  • Colorectal Cancer
  • Grand Rapids, Michigan
  • +2 more
Dec 21, 2022